Christopher M. Murphy
Chief Financial OfficerMr. Christopher M. Murphy, also known as Chris, is Chief Financial Officer of AnaptysBio, Inc. from May 11, 2026. He was Chief Financial & Business Officer of Third Harmonic Bio, Inc. from January 2024. He served as a member of the leadership team that transformed Horizon Therapeutics PLC from a primary care-focused specialty pharmaceutical company with a market capitalization of approximately 800 million to a fully integrated, highly profitable rare disease-focused biopharmaceutical company, which was acquired by Amgen Inc. in October 2023. While at Horizon, he served in roles of increasing responsibility in business development and commercial operations. Mr. Murphy held positions of increasing responsibility at Horizon Therapeutics PLC, or Horizon, from March 2014 to May 2020, serving as vice president, Business Development from March 2014 to November 2015, group vice president, Corporate Development from November 2015 to October 2017, group vice president of Operations, Inflammation Business Unit from October 2017 to June 2018 and most recently as group vice president, Commercial Operations and Analytics from June 2018 to May 2020. Prior to Horizon, Mr. Murphy held positions of increasing responsibility in the Life Sciences Investment Banking Group at JMP Securities LLC, or JMP, from July 2008 to March 2014, serving most recently as a director. Mr. Murphy holds a B.B.A. in Finance from the University of Notre Dame.
Positions
- Company NameAnaptysBio, Inc.Stock CodeANABPositionChief Financial OfficerColleagues
